What is Drugs Made In America Acquisition Corp. Ordinary Shares's share price today?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) share price today is $10.88 as of October 26, 2026 at 11:11 PM IST. The stock touched a day high of $10.88 and a day low of $10.88.What exchange does Drugs Made In America Acquisition Corp. Ordinary Shares stock trade on, and under what ticker symbol?
Drugs Made In America Acquisition Corp. Ordinary Shares stock trades on NASDAQ under the ticker symbol DMAA.What is Drugs Made In America Acquisition Corp. Ordinary Shares's market capitalization?
Drugs Made In America Acquisition Corp. Ordinary Shares's market capitalization is $264.01M as of October 26, 2026 at 11:11 PM IST.What is Drugs Made In America Acquisition Corp. Ordinary Shares's price-to-earnings (P/E) ratio?
Drugs Made In America Acquisition Corp. Ordinary Shares's price-to-earnings (P/E) ratio is 60.41 as of October 26, 2026.What is Drugs Made In America Acquisition Corp. Ordinary Shares's price-to-book (P/B) ratio?
Drugs Made In America Acquisition Corp. Ordinary Shares's price-to-book (P/B) ratio is 1.91 as of October 26, 2026.Can Indian investors buy Drugs Made In America Acquisition Corp. Ordinary Shares shares?
Yes, You can buy Drugs Made In America Acquisition Corp. Ordinary Shares shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Drugs Made In America Acquisition Corp. Ordinary Shares shares from India?
Indian investors can buy Drugs Made In America Acquisition Corp. Ordinary Shares shares in three steps: 1. Search Drugs Made In America Acquisition Corp. Ordinary Shares on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Drugs Made In America Acquisition Corp. Ordinary Shares shares for Indian investors?
Since Drugs Made In America Acquisition Corp. Ordinary Shares trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Drugs Made In America Acquisition Corp. Ordinary Shares shares via Tickertape?
Indian investors can start investing in Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.919 shares at the current price of $10.88.
$
₹
$10.880.05% (+0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
60.41
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
1.91
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$0.18
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
0%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Company Profile
Company Profile
UBS
P/E Ratio
15.77
15.77
1Y Return
21.32%
21.32%
Buy Reco %
33.33
33.33
P/E Ratio
8.14
8.14
1Y Return
6.53%
6.53%
Buy Reco %
50.00
50.00
P/E Ratio
—
—
1Y Return
49.04%
49.04%
Buy Reco %
60.52
60.52
FRMI
F
P/E Ratio
—
—
1Y Return
87.14%
87.14%
Buy Reco %
75.00
75.00
P/E Ratio
33.96
33.96
1Y Return
3.24%
3.24%
Buy Reco %
—
—
Forecast
Forecast
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
| Financial Year | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | - | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Net Income | -0 | -0.14 | -0 | 1.25 | 2.28 | 2.18 | 0.21 | 1.97 | 1.72 |
| Net Profit Margin | - | - | - | - | - | - | - | - | - |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
Financial ServicesShell Companies
Financial ServicesShell Companies
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Drugs Made In America Acquisition Corp. Ordinary Shares | 60.41 | 1.91 | - |
| UBS Group AG | 15.77 | 1.68 | 0.68 |
| Deutsche Bank AG | 8.14 | 0.78 | 1.58 |
Price Comparison
Price Comparison
Compare DMAA with any stock or ETFCompare DMAA with any stock or ETF
Comparing from
DMAA
UBS
DB